Pablo-Antonio U. T.
- Country
- France
- Department
- Dialyse
Research Overview
- Stroke prophylaxis with Apixaban in Chronic Kidney Disease stage 5 patients with Atrial fibrillation (SACK)
- Efficacy and Safety Evaluation of Inaxaplin (VX-147) in APOL1-Mediated Proteinuric Kidney Disease: A Phase 2/3 Adaptive, Double-Blind, Placebo-Controlled Study
- Evaluation of Safety and Tolerability of MZE829 in Adults with Proteinuric APOL1-Associated Chronic Kidney Disease: A Phase 2 Open-Label Study
Data & Insights
Has run more than one trial at 10 of 245 partner sites.
Specializations
Kidney Disease Research
The investigator specializes in studying innovative treatments for APOL1-mediated proteinuric kidney disease, focusing on therapeutic approaches for both adult and pediatric populations.
- Genetic kidney disorders
- Proteinuric conditions
- Pediatric nephrology
Their research encompasses comprehensive evaluation of novel therapeutic agents targeting specific genetic kidney conditions.
Cardiovascular Research
The investigator conducts research in atherosclerotic cardiovascular disease with particular emphasis on patients with end-stage kidney disease (ESKD) undergoing dialysis treatment.
- Cardiovascular complications in ESKD
- Dialysis therapy
- Inflammatory markers
Their work extends to investigating therapeutic interventions aimed at reducing cardiovascular risk in dialysis patients.
Clinical Applications
The investigator focuses on developing therapeutic interventions for complex medical conditions involving both kidney and cardiovascular systems.
- Combined organ system approaches
- Biomarker research
- Treatment optimization
Their research involves evaluating novel therapeutic agents and their effects on specific disease markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.